{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:40:53Z","timestamp":1776688853527,"version":"3.51.2"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypertension is highly prevalent and a major contributor to cardiovascular mortality and morbidity. In spite of the availability of efficacious, safe and affordable anti-hypertensive drugs, hypertension remains poorly controlled in the majority of hypertensive patients. Various reasons including non-adherence to the anti-hypertensive drugs, account for the poor control. Resistant hypertension is also one of the reasons for poor control of blood pressure (BP). The sympathetic nervous system (SNS) has long been recognized as one of the determinants in the pathophysiology of a raised BP. Overactivity of the SNS is a contributor to sustained arterial hypertension. Renal denervation (RDN) is increasingly recognized as a safe and effective adjunctive therapy to control BP with or without pharmacotherapy. Hence for patients who remain uncontrolled despite all efforts, renal denervation (RDN) is a novel treatment that can potentially improve BP control, hence reducing the major adverse cardiovascular events (MACE). More recent randomized, sham control trials of RDN have shown that RDN produces a sustained lowering of BP. To date, this lowering of BP through RDN is maintained for at least 3 years. Furthermore, this procedure has been found to be safe. Hence this consensus summarises the science behind RDN and the available clinical data to support the use of this therapy. It is hoped that this consensus will offer guidance on the importance of identifying patients who will benefit most from this therapy. A multidisciplinary team approach in the management of the patient undergoing RDN is recommended.<\/jats:p>","DOI":"10.1038\/s41440-022-00937-w","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T08:38:55Z","timestamp":1654072735000},"page":"1111-1122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension"],"prefix":"10.1038","volume":"45","author":[{"given":"Yook Chin","family":"Chia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Azman","family":"Wan Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Yean Yip","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azhari","family":"Rosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rashid","family":"Abdul Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gim Hooi","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Kun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Zawawi","family":"Abu Bakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiong Kiam","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"937_CR1","unstructured":"2019 National Health and Morbidity Survey Malaysia. https:\/\/ikumohgovmy\/images\/IKU\/Document\/REPORT\/NHMS2019\/Report_NHMS2019-NCD_v2pdf."},{"key":"937_CR2","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13\u2013e115. https:\/\/www.ahajournals.doi\/doi\/abs\/10.1161\/HYP.0000000000000065. Last accessed 11 Jan 2022.","journal-title":"Hypertension."},{"key":"937_CR3","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021\u2013104. https:\/\/academic.oup.com\/eurheartj\/article\/39\/33\/\/5079119?login=true. Last accessed 11 Jan 2022.","journal-title":"Eur Heart J."},{"key":"937_CR4","unstructured":"2018 Malaysian Clinical Practice Guidelines on the Management of Hypertension http:\/\/www.acadmedorgmy\/indexcfm?&menuid=67."},{"key":"937_CR5","unstructured":"2021 WHO Guideline for the pharmacological treatment of hypertension in adults. https:\/\/appswhoint\/iris\/bitstream\/handle\/10665\/344424\/9789240033986-engpdf."},{"key":"937_CR6","doi-asserted-by":"crossref","unstructured":"Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. Journal of the American Society of Hypertension. 2016;10:493\u20139. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S193317111630225X. Last accessed 11 Jan 2022.","DOI":"10.1016\/j.jash.2016.03.186"},{"key":"937_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403\u201319. https:\/\/pubmed.ncbi.nlm.nih.gov\/18574054\/. Last accessed 11 Jan 2022.","journal-title":"Hypertension"},{"key":"937_CR8","doi-asserted-by":"crossref","unstructured":"de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898\u2013902. https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.110.168948 . Last accessed 11 Jan 2022.","DOI":"10.1161\/HYPERTENSIONAHA.110.168948"},{"key":"937_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2296-15-131","volume":"15","author":"YC Chia","year":"2014","unstructured":"Chia YC, Ching SM. Prevalence and predictors of resistant hypertension in a primary care setting: a cross-sectional study. BMC Fam Pract 2014;15:1\u20137. https:\/\/link.springer.com\/article\/10.1186\/471-2296-15-131 Last accessed 11 Jan 2022.","journal-title":"BMC Fam Pract"},{"key":"937_CR10","first-page":"1","volume":"54","author":"N Kumar","year":"2020","unstructured":"Kumar N, Devaraj ZA, Tajudin TR, Teoh SH, Khan AH, Khan. Y. The prevalence of apparent resistant hypertension and associated factors among elderly hypertensive patients at two primary care clinicsin klang valley, Malaysia. Sapporo Med J. 2020;54:1\u20139.","journal-title":"Sapporo Med J"},{"key":"937_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1161\/HYPERTENSIONAHA.109.138610","volume":"54","author":"MP Schlaich","year":"2009","unstructured":"Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009;54:1195\u2013201. https:\/\/www.ahajournals.org\/doi\/full\/10.61\/HYPERTENSIONAHA.109.138610. Last accessed 11 Jan 2022.","journal-title":"Hypertension"},{"key":"937_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/HYPERTENSIONAHA.118.11203","volume":"71","author":"K Kario","year":"2018","unstructured":"Kario K, Wang JG. Could 130\/80 mm Hg Be adopted as the diagnostic threshold and management goal of hypertension in consideration of the characteristics of asian populations? Hypertension. 2018;71:979\u201384.","journal-title":"Hypertension."},{"key":"937_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41440-021-00751-w","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Wang T-D. Perspectives of renal denervation from hypertension to heart failure in Asia. Hypertension Res. 2022;45:193\u20137.","journal-title":"Hypertension Res"},{"key":"937_CR14","doi-asserted-by":"crossref","unstructured":"Mahfoud F, B\u00f6hm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40:3474\u201382. https:\/\/academic.oup.com\/eurheartj\/article\/40\/42\/\/5418594?login=truehttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6837160\/pdf\/ehz118.pdf. Last accessed: 11 Jan 2022.","DOI":"10.1093\/eurheartj\/ehz118"},{"key":"937_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41440-021-00683-5","volume":"44","author":"BK Kim","year":"2021","unstructured":"Kim BK, Kim HS, Park SJ, Park CG, Seung KB, Gwon HC, et al. Long-term outcomes after renal denervation in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). Hypertens Res. 2021;44:1099\u2013104.","journal-title":"Hypertens Res"},{"key":"937_CR16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","volume":"399","author":"F Mahfoud","year":"2022","unstructured":"Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399:1401\u201310.","journal-title":"Lancet"},{"key":"937_CR17","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1016\/j.jcin.2020.09.054","volume":"13","author":"M Azizi","year":"2020","unstructured":"Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, et al. 12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation. JACC Cardiovasc Interv. 2020;13:2922\u201333.","journal-title":"JACC Cardiovasc Interv"},{"key":"937_CR18","doi-asserted-by":"publisher","first-page":"B152-B","DOI":"10.1016\/j.jacc.2021.09.1222","volume":"78","author":"F Rader","year":"2021","unstructured":"Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, et al. TCT-369 durability of reduced office-measured blood pressure and antihypertensive medication use after ultrasound renal denervation: 24-month results from the RADIANCE-HTN SOLO trial. J Am Coll Cardiol. 2021;78:B152-B.","journal-title":"J Am Coll Cardiol."},{"key":"937_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/HYPERTENSIONAHA.119.13616","volume":"74","author":"TE hang","year":"2019","unstructured":"Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, et al. National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015. Hypertension. 2019;74:1324\u201332. https:\/\/www.ahajournals.org\/doi\/epub\/10.1161\/HYPERTENSIONAHA.119.13616 accessed 14 May 2022","journal-title":"Hypertension"},{"key":"937_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/jch.14212","volume":"23","author":"YC Chia","year":"2021","unstructured":"Chia YC, Devaraj NK, Ching SM, Ooi PB, Chew MT, Chew BN, et al. Relationship of an adherence score with blood pressure control status among patients with hypertension and their determinants: Findings from a nationwide blood pressure screening program. J Clin Hypertens. 2021;23:638\u201345.","journal-title":"J Clin Hypertens"},{"key":"937_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/HJH.0000000000002592","volume":"39","author":"RE Schmieder","year":"2021","unstructured":"Schmieder RE, Kandzari DE, Wang T-D, Lee Y-H, Lazarus G, Pathak A. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertension. 2021;39:162 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7752236\/. Last accessed 11 Jan 2022.","journal-title":"J Hypertension"},{"key":"937_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41440-021-00760-9","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45:232\u201340.","journal-title":"Hypertens Res"},{"key":"937_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41440-021-00828-6","volume":"45","author":"TD Wang","year":"2022","unstructured":"Wang TD. Patient preference: messages for the wider adoption of renal denervation in the real world. Hypertens Res. 2022;45:244\u20135.","journal-title":"Hypertens Res"},{"key":"937_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","volume":"124","author":"MC Acelajado","year":"2019","unstructured":"Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circulation Res. 2019;124:1061\u201370. https:\/\/www.ahajournals.org\/doi\/pdf\/10.161\/CIRCRESAHA.118.312156?download=true. Last accessed 11 Jan 2022.","journal-title":"Circulation Res"},{"key":"937_CR25","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jch.13415","volume":"20","author":"K Kario","year":"2018","unstructured":"Kario K, Tomitani N, Buranakitjaroen P, Chia Y-C, Park S, Chen C-H, et al. Home blood pressure control status in 2017-2018 for hypertension specialist centers in Asia: Results of the Asia BP@Home study. J Clin Hypertens. 2018;20:1686\u201395.","journal-title":"J Clin Hypertens"},{"key":"937_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/jch.13721","volume":"22","author":"YC Chia","year":"2020","unstructured":"Chia YC, Kario K. Asian management of hypertension: current status, home blood pressure, and specific concerns in Malaysia. J Clin Hypertens. 2020;22:497\u2013500.","journal-title":"J Clin Hypertens"},{"key":"937_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08037051.2019.1608134","volume":"28","author":"V Pallar\u00e9s-Carratal\u00e1","year":"2019","unstructured":"Pallar\u00e9s-Carratal\u00e1 V, Bonig-Trigueros I, Palaz\u00f3n-Bru A, Esteban-Giner MJ, Gil-Guill\u00e9n VF, Giner-Galva\u00f1 V. Clinical inertia in hypertension: a new holistic and practical concept within the cardiovascular continuum and clinical care process. Blood Press. 2019;28:217\u201328.","journal-title":"Blood Press"},{"key":"937_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2296-15-130","volume":"15","author":"JP Lebeau","year":"2014","unstructured":"Lebeau JP, Cadwallader JS, Aubin-Auger I, Mercier A, Pasquet T, Rusch E, et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract. 2014;15:130.","journal-title":"BMC Fam Pract"},{"key":"937_CR29","unstructured":"World Health Organization. Adherence to long-term therapies : evidence for action \/. Sabate E, editor. World Health Organization; 2003. https:\/\/apps.who.int\/iris\/handle\/10665\/42682"},{"key":"937_CR30","first-page":"613","volume":"6","author":"A Ramli","year":"2012","unstructured":"Ramli A, Ahmad NS, Paraidathathu T. Medication adherence among hypertensive patients of primary health clinics in Malaysia. Patient Prefer Adherence. 2012;6:613 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3437910\/. Last accessed 11 Jan 2022.","journal-title":"Patient Prefer Adherence"},{"key":"937_CR31","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1097\/01.hjh.0000420060.44048.94","volume":"30","author":"AH Arshad","year":"2012","unstructured":"Arshad AH, Lau GC, Yahya SA, Hussin A, Rahman RA, Zambahari R. The prevalence of white-coat resistant hypertension (wc-rh) amongst patients referred for cathether-based renal denervation (rdn) procedure for true resistant hypertension (trh) at the national heart institute of Malaysia. J Hypertension. 2012;30:e89 https:\/\/journals.lww.com\/jhypertension\/Abstract\/2012\/09001\/300_THE_PREVALENCE_OF_WHITE_COAT_RESISTANT.285.aspx. Last accessed 11 Jan 2022.","journal-title":"J Hypertension"},{"key":"937_CR32","doi-asserted-by":"crossref","unstructured":"Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691\u20137. https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.113.01448. Last accessed 11 Jan 2022.","DOI":"10.1161\/HYPERTENSIONAHA.113.01448"},{"key":"937_CR33","unstructured":"Shyuan TH, Ariffin AA, Zulkefli NAM, Mustapha FI. Predictors of uncontrolled hypertension among patients receiving treatment from public primary care clinics in Pulau Pinang, Malaysia. Malays J Med Health Sci. 2020;16. http:\/\/psasir.upm.edu.my\/id\/eprint\/90305\/1\/32upm.pdf. Last accessed 11 Jan 2022."},{"key":"937_CR34","unstructured":"Grossman A, Messerli FH, Grossman E. Drug induced hypertension\u2013an unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763:15\u201322. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0014299915300893?casa_token=8GKeaCH29XwAAAAA:uB1oCN3Fy1TsWQhqWedzmTDk_iYOlZikj4OvpKYa1nLcxlYOpleiZ0V-zTB2yjjPDXAjnYmOhttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S?via%3Dihub. Last accessed 11 Jan 2022."},{"key":"937_CR35","unstructured":"Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet. 2009;373:1275\u201381. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673609605663?casa_token=ysXqshsq6y8AAAAA:uiLuqPhay6GdqD_flO-q48ZKQEnqsjldcA0ubcZGlns06m9FrEZprIddySHIRQU0L1KnoddShttps:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(09)60566-3\/fulltext. Last accessed 11 Jan 2022."},{"key":"937_CR36","doi-asserted-by":"crossref","unstructured":"Esler MD, Krum H, Schlaich M, Schmieder RE, B\u00f6hm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976\u201382. https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.112.130880. Last accessed 11 Jan 2022.","DOI":"10.1161\/CIRCULATIONAHA.112.130880"},{"key":"937_CR37","doi-asserted-by":"crossref","unstructured":"Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circulation research. 2015;116:1074\u201395. https:\/\/www.ahajournals.org\/doi\/full\/10.161\/CIRCRESAHA.116.303603. Last accessed 11 Jan 2022.","DOI":"10.1161\/CIRCRESAHA.116.303603"},{"key":"937_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41440-021-00827-7","volume":"45","author":"K Katsurada","year":"2022","unstructured":"Katsurada K, Shinohara K, Aoki J, Nanto S, Kario K. Renal denervation: basic and clinical evidence. Hypertens Res. 2022;45:198\u2013209.","journal-title":"Hypertens Res"},{"key":"937_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s41440-021-00746-7","volume":"44","author":"K Katsurada","year":"2021","unstructured":"Katsurada K, Ogoyama Y, Imai Y, Patel KP, Kario K. Renal denervation based on experimental rationale. Hypertens Res. 2021;44:1385\u201394.","journal-title":"Hypertens Res"},{"key":"937_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jcin.2019.02.050","volume":"12","author":"MA Weber","year":"2019","unstructured":"Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, et al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv 2019;12:1095\u2013105. Link available at: 10.16\/j.jcin.2019.02.050. Last accessed 11 Jan 2022.","journal-title":"JACC Cardiovasc Interv"},{"key":"937_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41440-021-00761-8","volume":"45","author":"Y Ogoyama","year":"2022","unstructured":"Ogoyama Y, Tada K, Abe M, Nanto S, Shibata H, Mukoyama M, et al. Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res. 2022;45:210\u201320.","journal-title":"Hypertens Res"},{"key":"937_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41440-021-00754-7","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45:221\u201331.","journal-title":"Hypertens Res"},{"key":"937_CR43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jcin.2019.10.048","volume":"13","author":"F Mahfoud","year":"2020","unstructured":"Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, B\u00f6hm M, et al. Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv. 2020;13:471\u201384.","journal-title":"JACC Cardiovasc Interv"},{"key":"937_CR44","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","volume":"390","author":"RR Townsend","year":"2017","unstructured":"Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160\u201370. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S014067361732281X?casa_token=tVa_x0PraLIAAAAA:IXv1rszTaJ0kd3uXLRDVAFfjszHI1LECarPaLNn_RBluvHblUHbAPauuD2ednXW5nbeIkYxd Last accessed 11 Jan 2022.","journal-title":"Lancet"},{"key":"937_CR45","unstructured":"Kandzari DE, B\u00f6hm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346\u201355. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673618309516?casa_token=HFGX6OiuyC4AAAAA:UPLRDVBABJIiROIKvcFJqvPLHRR9U7VpTtRY6-FiX1VmhFTq7xBvYyR2kwKAbJ2-gPy4gf3fhttps:\/\/core.ac.uk\/download\/158172511.pdf. Last accessed 11 Jan 2022."},{"key":"937_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41440-021-00814-y","volume":"45","author":"MA Weber","year":"2022","unstructured":"Weber MA. Hypertension research from Japan: advancing the field of renal denervation. Hypertens Res. 2022;45:188\u201392.","journal-title":"Hypertens Res"},{"key":"937_CR47","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393\u2013401. https:\/\/www.nejm.org\/doi\/full\/10.056\/NEJMoa1402670https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa?articleTools=true. Last accessed 11 Jan 2022.","DOI":"10.1056\/NEJMoa1402670"},{"key":"937_CR48","doi-asserted-by":"crossref","unstructured":"Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219\u201327. https:\/\/academic.oup.com\/eurheartj\/article\/36\/4\/\/2293381?login=truehttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4301597\/pdf\/ehu441.pdf. Last accessed 11 Jan 2022.","DOI":"10.1093\/eurheartj\/ehu441"},{"key":"937_CR49","doi-asserted-by":"crossref","unstructured":"Mahfoud F, Schmieder RE, Azizi M, Pathak A, Sievert H, Tsioufis C, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017;38:3272\u201381. https:\/\/academic.oup.com\/eurheartj\/article\/38\/44\/\/3798693?login=true. Last accessed 11 Jan 2022.","DOI":"10.1093\/eurheartj\/ehx215"},{"key":"937_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41440-021-00808-w","volume":"45","author":"RE Schmieder","year":"2022","unstructured":"Schmieder RE, Bosch A. Editorial comment: Renal denervation. Hypertens Res. 2022;45:241\u20133.","journal-title":"Hypertens Res"},{"key":"937_CR51","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444\u201351.","journal-title":"Lancet."},{"key":"937_CR52","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335\u201345. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673618310821?casa_token=XKA9iIjbvbEAAAAA:XbTivVOUa_DCJghLJ2JidDsjpXifRyRyyisGvhSrpRJddSOXyAEWz-LkQfHALbKeID22WBbo. Last accessed 11 Jan 2022."},{"key":"937_CR53","first-page":"461","volume":"13","author":"MA Weber","year":"2020","unstructured":"Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, et al. The REDUCE HTN: REINFORCE: randomized, sham-controlled trial of bipolar radiofrequency renal denervation for the treatment of hypertension. Cardiovasc Interv. 2020;13:461\u201370. https:\/\/www.jacc.org\/10.1016\/j.jcin.2019.10.061 Last accessed 11 Jan 2022.","journal-title":"Cardiovasc Interv"},{"key":"937_CR54","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021. https:\/\/www.thelancetcom\/journals\/lancet\/article\/PIIS0140-6736(21)00788-1\/fulltext. Last accessed 11 Jan 2022."},{"key":"937_CR55","doi-asserted-by":"crossref","unstructured":"Schmieder R, Mahfoud F, Azizi M, Pathak A, Dimitriadis K, Kroon A, et al. Members of the ESH Working Group on Interventional Treatment of Hypertension. European Society of Hypertension position paper on renal denervation. 2018:2042\u20138. https:\/\/www.eshonline.org\/esh-content\/uploads\/19\/02\/WG-on-Interventional-Treatment-of-Hypertension.pdf. Last accessed 11 Jan 2022.","DOI":"10.1097\/HJH.0000000000001858"},{"key":"937_CR56","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","volume":"32","author":"C Thomopoulos","year":"2014","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285\u201395. https:\/\/journals.lww.com\/jhypertension\/FullText\/014\/12000\/Effects_of_blood_pressure_lowering_on_outcome.2.aspx?casa_token=sML50KvJYxsAAAAA:lU6QusZJOdnGba-nYCH5iMmF1S2bP3Y1UIyePZjdQnEksjQipFlibD_vYRldgGJ7CjL3bmNprSrZRfF8LQpPnQ. Last accessed 11 Jan 2022.","journal-title":"J Hypertens"},{"key":"937_CR57","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673615012258?casa_token=agcUVbueYTYAAAAA:CLoZ1Whb4sNYokSwHrcI39eH79O_o_K7c-GauJ11f-A3xMhh_TKWarGyliDA1fwKAgO1U_9https:\/\/www.thelancet.com\/pdfs\/journals\/lancet\/PIIS0140-6736(15)01225-8.pdf. Last accessed 11 Jan 2022."},{"key":"937_CR58","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.","journal-title":"BMJ."},{"key":"937_CR59","unstructured":"2020 Health Facts for Malaysia: Reference Data for 2019 Ministry of Health Malaysia. https:\/\/appswhoint\/iris\/bitstream\/handle\/10665\/344424\/9789240033986-engpdf."},{"key":"937_CR60","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/HYPERTENSIONAHA.115.06260","volume":"66","author":"K Kario","year":"2015","unstructured":"Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of catheter-based renal denervation on morning and nocturnal blood pressure. Hypertension. 2015;66:1130\u20137.","journal-title":"Hypertension."},{"key":"937_CR61","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1161\/CIRCULATIONAHA.118.035588","volume":"138","author":"K Kario","year":"2018","unstructured":"Kario K, B\u00f6hm M, Mahfoud F, Townsend RR, Weber MA, Patel M, et al. Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED trial. Circulation. 2018;138:1602\u20134.","journal-title":"Circulation."},{"key":"937_CR62","doi-asserted-by":"crossref","unstructured":"Kario K, Weber MA, Mahfoud F, Kandzari DE, Schmieder RE, Kirtane AJ, et al. Changes in 24-hour patterns of blood pressure in hypertension following renal denervation therapy. Hypertension. 2019;74:Hypertensionaha11913081.","DOI":"10.1161\/HYPERTENSIONAHA.119.13081"},{"key":"937_CR63","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00392-020-01718-6","volume":"110","author":"K Kario","year":"2021","unstructured":"Kario K, Weber MA, B\u00f6hm M, Townsend RR, Mahfoud F, Schmieder RE, et al. Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. Clin Res Cardiol. 2021;110:725\u201331.","journal-title":"Clin Res Cardiol"},{"key":"937_CR64","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","volume":"77","author":"N Fatani","year":"2021","unstructured":"Fatani N, Dixon DL, Van Tassell BW, Fanikos J, Buckley LF. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension. J Am Coll Cardiol. 2021;77:1290\u20139. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0735109721000802?via%3Dihub. Last accessed 11 Jan 2022.","journal-title":"J Am Coll Cardiol"},{"key":"937_CR65","doi-asserted-by":"publisher","first-page":"e1496","DOI":"10.4244\/EIJ-D-20-01090","volume":"16","author":"DE Kandzari","year":"2021","unstructured":"Kandzari DE, Hickey GL, Pocock SJ, Weber MA, B\u00f6hm M, Cohen SA, et al. Prioritised endpoints for device-based hypertension trials: the win ratio methodology. EuroIntervention. 2021;16:e1496\u2013e502.","journal-title":"EuroIntervention"},{"key":"937_CR66","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016;134:441\u201350.","journal-title":"Circulation"},{"key":"937_CR67","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/jch.13058","volume":"19","author":"YC Chia","year":"2017","unstructured":"Chia YC, Buranakitjaroen P, Chen CH, Divinagracia R, Hoshide S, Park S, et al. Current status of home blood pressure monitoring in Asia: statement from the HOPE Asia Network. J Clin Hypertens. 2017;19:1192\u2013201.","journal-title":"J Clin Hypertens"},{"key":"937_CR68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223\u201337.","journal-title":"Nat Rev Nephrol."},{"key":"937_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"NCD-RisC). NRFC.","year":"2017","unstructured":"(NCD-RisC). NRFC. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants. Lancet. 2017;389:37\u201355.","journal-title":"Lancet."},{"key":"937_CR70","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41440-020-0508-z","volume":"43","author":"T Hisamatsu","year":"2020","unstructured":"Hisamatsu T, Segawa H, Kadota A, Ohkubo T, Arima H, Miura K. Epidemiology of hypertension in Japan: beyond the new 2019 Japanese guidelines. Hypertens Res. 2020;43:1344\u201351.","journal-title":"Hypertens Res"},{"key":"937_CR71","unstructured":"Department of Economic and Social Affairs, Population Division, United Nations. World Population Prospects 2019. https:\/\/populationunorg\/wpp\/."},{"key":"937_CR72","unstructured":"Population and aging in Asia: the growing elderly population. Asia Development Bank; 2018. https:\/\/data.adb.org\/dataset\/population-and-aging-asia-and-pacific."},{"key":"937_CR73","unstructured":"Global Age Watch https:\/\/data.adb.org\/dataset\/population-and-aging-asia-and-pacific. Accessed 9 Aug 2021."},{"key":"937_CR74","unstructured":"National Health and Morbidity Survey 2019. In: National Institutes of Health (NIH) MoHM, editor. 2019. https:\/\/iku.moh.gov.my\/images\/IKU\/Document\/REPORT\/NHMS2019\/Report_NHMS-NCD_v2.pdf. Last accessed 11 Jan 2022."},{"key":"937_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46965-4","volume":"9","author":"S-H Kang","year":"2019","unstructured":"Kang S-H, Kim S-H, Cho JH, Yoon C-H, Hwang S-S, Lee H-Y, et al. Prevalence, awareness, treatment, and control of hypertension in Korea. Sci Rep. 2019;9:10970.","journal-title":"Sci Rep"},{"key":"937_CR76","volume-title":"Hypertension fact sheet.","author":"WHO.","year":"2021","unstructured":"WHO. Hypertension fact sheet. WHO Publication; 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension"},{"key":"937_CR77","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/bmj.297.6644.319","volume":"297","author":"Intersalt: an international study of electrolyte excretion and blood pressure.","year":"1988","unstructured":"Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24h urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ (Clin Res ed) 1988;297:319\u201328.","journal-title":"BMJ (Clin Res ed)"},{"key":"937_CR78","first-page":"570","volume":"14","author":"J Stamler","year":"1989","unstructured":"Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings. Public Health Med care Implic Hypertens. 1989;14:570\u20137.","journal-title":"Public Health Med care Implic Hypertens"},{"key":"937_CR79","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/sj.jhh.1001605","volume":"17","author":"BF Zhou","year":"2003","unstructured":"Zhou BF, Stamler J, Dennis B, Moag-Stahlberg A, Okuda N, Robertson C, et al. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. J Hum Hypertens. 2003;17:623\u201330.","journal-title":"J Hum Hypertens"},{"key":"937_CR80","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/HYPERTENSIONAHA.115.05958","volume":"66","author":"S Hoshide","year":"2015","unstructured":"Hoshide S, Kario K, de la Sierra A, Bilo G, Schillaci G, Banegas Jos\u00e9 R, et al. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects. Hypertension. 2015;66:750\u20136.","journal-title":"Hypertension."},{"key":"937_CR81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PPA.S94687","volume":"10","author":"A Abdullah","year":"2016","unstructured":"Abdullah A, Liew SM, Hanafi NS, Ng CJ, Lai PSM, Chia YC, et al. What influences patients\u2019 acceptance of a blood pressure telemonitoring service in primary care? A qualitative study. Patient Prefer Adherence. 2016;10:99.","journal-title":"Patient Prefer Adherence"},{"key":"937_CR82","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","volume":"34","author":"R Chowdhury","year":"2013","unstructured":"Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/23907142\/. Last accessed 11 Jan 2022.","journal-title":"Eur Heart J"},{"key":"937_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jash.2011.01.001","volume":"5","author":"MN Hill","year":"2011","unstructured":"Hill MN, Miller NH, Degeest S, Materson BJ, Black HR, Izzo JL Jr., et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011;5:56\u201363.","journal-title":"J Am Soc Hypertens"},{"key":"937_CR84","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1097\/01.hjh.0000187261.40190.2e","volume":"23","author":"BL Van Wijk","year":"2005","unstructured":"Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23:2101\u20137.","journal-title":"J Hypertens"},{"key":"937_CR85","first-page":"119","volume":"6","author":"D Urban","year":"2013","unstructured":"Urban D, Ewen S, Ukena C, Linz D, B\u00f6hm M, Mahfoud F. Treating resistant hypertension: role of renal denervation. Integr Blood Press Control. 2013;6:119\u201328.","journal-title":"Integr Blood Press Control"},{"key":"937_CR86","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1573402112666160302102841","volume":"12","author":"K Kario","year":"2016","unstructured":"Kario K, Okura A, Okawara Y, Tomitani N, Ikemoto T, Hoshide S. Impact of introducing catheter-based renal denervation into Japan for hypertension management: Estimation of number of target patients and clinical relevance of ambulatory blood pressure reduction. Curr hypertension Rev. 2016;12:156\u201363. https:\/\/academic.oup.com\/eurheartj\/article\/32\/20\/2499\/486540?login=true. Last accessed 11 Jan 2022.","journal-title":"Curr hypertension Rev"},{"key":"937_CR87","doi-asserted-by":"crossref","unstructured":"Mann SJ. Neurogenic hypertension: pathophysiology, diagnosis and management. Clin Auton Res. 2018;28:363-74. https:\/\/pubmed.ncbi.nlm.nih.gov\/29974290\/https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-018-0541-z.pdf. Last accessed 11 Jan 2022.","DOI":"10.1007\/s10286-018-0541-z"},{"key":"937_CR88","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/eurheartj\/ehz027","volume":"40","author":"M Esler","year":"2019","unstructured":"Esler M. Does increased 24-h ambulatory heart rate identify de facto neurogenic hypertension, and facilitate selection of hypertensive patients for renal denervation? Eur Heart J. 2019;40:752\u20134.","journal-title":"Eur Heart J"},{"key":"937_CR89","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.120.16378","volume":"77","author":"K Kario","year":"2021","unstructured":"Kario K, Hettrick DA, Prejbisz A, Januszewicz A. Obstructive sleep apnea-induced neurogenic nocturnal hypertension: a potential role of renal denervation? Hypertension. 2021;77:1047\u201360.","journal-title":"Hypertension."},{"key":"937_CR90","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","volume":"383","author":"H Krum","year":"2014","unstructured":"Krum H, Schlaich MP, Sobotka PA, B\u00f6hm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622\u20139. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673613621923?casa_token=f4GAUO-E7w0AAAAA:VjSkwrIrq0S5wXjIZHqoNTMOu5enx6p8HMioWxm-QTwQ3dOa2CRlgleBrmoVufYU7zb0sDuE9tI. Last accessed 11 Jan 2022.","journal-title":"Lancet"},{"key":"937_CR91","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"MD Esler","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903\u20139.","journal-title":"Lancet."},{"key":"937_CR92","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1590\/2175-8239-jbn-2018-0213","volume":"42","author":"MAP Fontes","year":"2020","unstructured":"Fontes MAP, Marzano LAS, Silva CC, Silva ACS. Renal sympathetic denervation for resistant hypertension: where do we stand after more than a decade. J Bras Nefrol. 2020;42:67\u201376.","journal-title":"J Bras Nefrol"},{"key":"937_CR93","doi-asserted-by":"crossref","unstructured":"Kario K, Kim B-K, Aoki J, Wong AY-T, Lee Y-H, Wongpraparut N, et al. Renal denervation in Asia: consensus statement of the Asia Renal Denervation Consortium. Hypertension. 2020;75:590\u2013602. https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.119.13671. Last accessed 11 Jan 2022.","DOI":"10.1161\/HYPERTENSIONAHA.119.13671"},{"key":"937_CR94","first-page":"199","volume":"35","author":"T-D Wang","year":"2019","unstructured":"Wang T-D, Lee Y-H, Chang S-S, Tung Y-C, Yeh C-F, Lin Y-H, et al. 2019 consensus statement of the Taiwan hypertension society and the Taiwan Society of Cardiology on renal denervation for the Management of Arterial Hypertension. Acta Cardiologica Sin 2019;35:199 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6533581\/. Last accessed 11 Jan 2022.","journal-title":"Acta Cardiologica Sin"},{"key":"937_CR95","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jacc.2021.06.044","volume":"78","author":"M B\u00f6hm","year":"2021","unstructured":"B\u00f6hm M, Tsioufis K, Kandzari DE, Kario K, Weber MA, Schmieder RE, et al. Effect of heart rate on the outcome of renal denervation in patients with uncontrolled hypertension. J Am Coll Cardiol. 2021;78:1028\u201338. https:\/\/pubmed.ncbi.nlm.nih.gov\/34474735\/. Last accessed 11 Jan 2022.","journal-title":"J Am Coll Cardiol"},{"key":"937_CR96","doi-asserted-by":"publisher","first-page":"e007062","DOI":"10.1161\/JAHA.117.007062","volume":"6","author":"PY Courand","year":"2017","unstructured":"Courand PY, Pereira H, Del Giudice C, Gosse P, Monge M, Bobrie G, et al. Abdominal aortic calcifications influences the systemic and renal hemodynamic response to renal denervation in the DENERHTN (renal denervation for hypertension) trial. J Am Heart Assoc. 2017;6:e007062 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5721886\/. Last accessed 11 Jan 2022.","journal-title":"J Am Heart Assoc"},{"key":"937_CR97","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/HJH.0000000000001739","volume":"36","author":"K Fengler","year":"2018","unstructured":"Fengler K, Rommel K-P, Blazek S, von Roeder M, Besler C, Hartung P, et al. Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation. J Hypertens. 2018;36:1578\u201384. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673613621923?casa_token=2aKKEkhbKbUAAAAA:GyAztcVqyGHTP5PK6Vhb3R8mCIvIRHbtmwJp2H_FQ2wOPmBHg-9T01hk3u3DQxWPCEjyNu2bnio Last accessed 11 Jan 2022.","journal-title":"J Hypertens"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00937-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00937-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00937-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T22:09:51Z","timestamp":1666735791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00937-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-00937-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y-CC has received an unrestricted educational grant for activities of the Malaysian Society for World Action on Salt, Sugar and Health (MyWASSH) and speaker honoraria from Medtronic All other authors do not have any conflict of interest in the writing of this consensus","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}